Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 38

Sort by

Sort Order Select

Meeting Abstracts

231-OR: Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2

RODOLFO J. GALINDO, W. TIMOTHY GARVEY, LISA M. NEFF, ADAM STEFANSKI, DACHUANG CAO, CLARE LEE

Diabetes 2024;73(Supplement_1):231-OR

https://doi.org/10.2337/db24-231-OR

Published: 14 June 2024

View articletitled, 231-OR: Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2

Meeting Abstracts

751-P: Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators—Exploratory Analysis of SURPASS 1–5 Trials

JULIO ROSENSTOCK, W. TIMOTHY GARVEY, RACHEL L. BATTERHAM, MINZHI LIU, BRANDON BERGMAN, ANDREA HEMMINGWAY, VIVIAN THIEU

Diabetes 2023;72(Supplement_1):751-P

https://doi.org/10.2337/db23-751-P

Published: 20 June 2023

View articletitled, 751-P: Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators—Exploratory Analysis of SURPASS 1–5 Trials

Meeting Abstracts

747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5

W. TIMOTHY GARVEY, RACHEL L. BATTERHAM, JULIO ROSENSTOCK, MINZHI LIU, VIVIAN THIEU, JACK DALY, BRANDON BERGMAN

Diabetes 2023;72(Supplement_1):747-P

https://doi.org/10.2337/db23-747-P

Published: 20 June 2023

View articletitled, 747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5

Meeting Abstracts

223-LB: Associations between Genetic Risk for Insulin Resistance and Measured Insulin Sensitivity Are Impacted by Race and BMI Status

MARIAN L. YURCHISHIN, LAUREN A. FOWLER, VIBHU PARCHA, PANKAJ ARORA, W. TIMOTHY GARVEY, BARBARA GOWER

Diabetes 2023;72(Supplement_1):223-LB

https://doi.org/10.2337/db23-223-LB

Published: 20 June 2023

View articletitled, 223-LB: Associations between Genetic Risk for Insulin Resistance and Measured Insulin Sensitivity Are Impacted by Race and BMI Status

Meeting Abstracts

71-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—SURMOUNT-1 Post Hoc Analysis by Prediabetes Status

EMILY R. HANKOSKY, HUI WANG, LISA M. NEFF, HONGJUN KAN, FANGYU WANG, NADIA AHMAD, ADAM STEFANSKI, W. TIMOTHY GARVEY

Diabetes 2023;72(Supplement_1):71-LB

https://doi.org/10.2337/db23-71-LB

Published: 20 June 2023

View articletitled, 71-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—SURMOUNT-1 Post Hoc Analysis by Prediabetes Status

Meeting Abstracts

70-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—Post Hoc Analysis of the SURMOUNT-1 Trial

EMILY R. HANKOSKY, HUI WANG, LISA M. NEFF, HONGJUN KAN, FANGYU WANG, NADIA AHMAD, ADAM STEFANSKI, W. TIMOTHY GARVEY

Diabetes 2023;72(Supplement_1):70-LB

https://doi.org/10.2337/db23-70-LB

Published: 20 June 2023

View articletitled, 70-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—Post Hoc Analysis of the SURMOUNT-1 Trial

Meeting Abstracts

51-LB: Race Specific Effects of a Carbohydrate-Restricted Diet on Acute and Maximal C Peptide Response to Glucose in Adults with Type 2 Diabetes

BARBARA GOWER, AMY M. GOSS, W. TIMOTHY GARVEY

Diabetes 2023;72(Supplement_1):51-LB

https://doi.org/10.2337/db23-51-LB

Published: 20 June 2023

View articletitled, 51-LB: Race Specific Effects of a Carbohydrate-Restricted Diet on Acute and Maximal C Peptide Response to Glucose in Adults with Type 2 Diabetes

Meeting Abstracts

1118-P: Prediction of Clamp-Derived Insulin Sensitivity in African Americans from Clinical Risk Factors

LAUREN A. FOWLER, VIBHU PARCHA, CATHARINE COUCH, W. TIMOTHY GARVEY, BARBARA GOWER

Diabetes 2022;71(Supplement_1):1118-P

https://doi.org/10.2337/db22-1118-P

Published: 01 June 2022

View articletitled, 1118-P: Prediction of Clamp-Derived Insulin Sensitivity in African Americans from Clinical Risk Factors

Meeting Abstracts

2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity

W. TIMOTHY GARVEY, THOMAS HOLST-HANSEN, PETER N. LAURSEN, ANDERS R. RINNOV, LUA J. WILKINSON

Diabetes 2022;71(Supplement_1):2-LB

https://doi.org/10.2337/db22-2-LB

Published: 01 June 2022

View articletitled, 2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity

Meeting Abstracts

1413-P: Semaglutide 2.4 mg Improved Glucose Metabolism and Reverted Prediabetes to Normoglycemia in Adults with Overweight/Obesity vs. Liraglutide 3.0 mg (STEP 8)

JULIO ROSENSTOCK, W. TIMOTHY GARVEY, BRYAN GOLDMAN, USMAN KHALID, RASMUS SØRRIG, DOMENICA RUBINO

Diabetes 2022;71(Supplement_1):1413-P

https://doi.org/10.2337/db22-1413-P

Published: 01 June 2022

View articletitled, 1413-P: Semaglutide 2.4 mg Improved Glucose Metabolism and Reverted Prediabetes to Normoglycemia in Adults with Overweight/Obesity vs. Liraglutide 3.0 mg (STEP 8)

Meeting Abstracts

1210-P: Associations between HbA1c, Area Level Social Vulnerability, and Poor COVID-Outcomes

CARRIE R. HOWELL, LI ZHANG, SHANQUELA WILLIAMS, NENGJUN YI, W. TIMOTHY GARVEY, ANDREA CHERRINGTON

Diabetes 2022;71(Supplement_1):1210-P

https://doi.org/10.2337/db22-1210-P

Published: 01 June 2022

View articletitled, 1210-P: Associations between HbA1c, Area Level Social Vulnerability, and Poor COVID-Outcomes

Meeting Abstracts

80-OR: Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis

ROBERT F. KUSHNER, MELANIE J. DAVIES, JOHN DEANFIELD, W. TIMOTHY GARVEY, OLE JEPPESEN, USMAN KHALID, MIKHAIL N. KOSIBOROD, PETER N. LAURSEN, DOMENICA RUBINO, SUBODH VERMA

Diabetes 2021;70(Supplement_1):80-OR

https://doi.org/10.2337/db21-80-OR

Published: 01 June 2021

View articletitled, 80-OR: Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis

Meeting Abstracts

83-OR: Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)

ILDIKO LINGVAY, LOUISE FÆRCH, ANNA KOROLEVA, ROBERT F. KUSHNER, CAREL LE ROUX, SOO LIM, OFRI MOSENZON, THOMAS A. WADDEN, SIGNE O.R. WALLENSTEIN, W. TIMOTHY GARVEY

Diabetes 2021;70(Supplement_1):83-OR

https://doi.org/10.2337/db21-83-OR

Published: 01 June 2021

View articletitled, 83-OR: Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)

Journal Articles

Tribbles Homolog 3 Mediates the Development and Progression of Diabetic Retinopathy

Priyamvada M. Pitale, Irina V. Saltykova, Yvonne Adu-Agyeiwaah, Sergio Li Calzi, Takashi Satoh, Shizuo Akira, Oleg Gorbatyuk, Michael E. Boulton, Machelle T. Pardue, W. Timothy Garvey, Mohammad Athar, Maria B. Grant, Marina S. Gorbatyuk

Diabetes 2021;70(8):1738–1753

https://doi.org/10.2337/db20-1268

Published: 11 May 2021

View articletitled, Tribbles Homolog 3 Mediates the Development and Progression of Diabetic Retinopathy

Meeting Abstracts

Serum Apolipoprotein C-III and Cardiovascular Events in Type 1 Diabetes

ARPITA BASU, IONUT BEBU, ALICIA JENKINS, JULIE STONER, YING ZHANG, RICHARD L. KLEIN, MARIA F. LOPES-VIRELLA, W. TIMOTHY GARVEY, MATTHEW BUDOFF, TIMOTHY LYONS, DCCT/EDIC RESEARCH GROUP

Diabetes 2018;67(Supplement_1):188-LB

https://doi.org/10.2337/db18-188-LB

Published: 01 July 2018

View articletitled, Serum Apolipoprotein C-III and Cardiovascular Events in Type 1 Diabetes

Meeting Abstracts

Cardiometabolic Disease Risk Assessment Predicts Incident Diabetes in a Large and Diverse Population

LUA WILKINSON, TAPAN MEHTA, W. TIMOTHY GARVEY

Diabetes 2018;67(Supplement_1):1548-P

https://doi.org/10.2337/db18-1548-P

Published: 01 July 2018

View articletitled, Cardiometabolic Disease Risk Assessment Predicts Incident Diabetes in a Large and Diverse Population

Meeting Abstracts

Uric Acid and Cardiovascular Disease in Type 1 Diabetes

ARPITA BASU, BARBARA BRAFFETT, ALICIA JENKINS, IONUT BEBU, RICHARD L. KLEIN, MARIA F. LOPES-VIRELLA, SAMUEL DAGOGO-JACK, TREVOR J. ORCHARD, AMISHA WALLIA, JOHN LACHIN, W. TIMOTHY GARVEY, TIMOTHY LYONS, DCCT/EDIC RESEARCH GROUP

Diabetes 2018;67(Supplement_1):189-LB

https://doi.org/10.2337/db18-189-LB

Published: 01 July 2018

View articletitled, Uric Acid and Cardiovascular Disease in Type 1 Diabetes

Meeting Abstracts

The Induction of TRIB3 Causing Glucose Toxicity in Muscle Requires the O-GlcNAcylation of SP1

XIAOBING LIU, MINSUNG KANG, W. TIMOTHY GARVEY

Diabetes 2018;67(Supplement_1):268-LB

https://doi.org/10.2337/db18-268-LB

Published: 01 July 2018

View articletitled, The Induction of TRIB3 Causing Glucose Toxicity in Muscle Requires the O-GlcNAcylation of SP1

Meeting Abstracts

Maternal Dietary Manipulation Programs Offspring’s Metabolism

MINSUNG KANG, JESSICA P. ANTIPENKO, XIAOBING LIU, KIRK M. HABEGGER, W. TIMOTHY GARVEY

Diabetes 2018;67(Supplement_1):281-LB

https://doi.org/10.2337/db18-281-LB

Published: 01 July 2018

View articletitled, Maternal Dietary Manipulation Programs Offspring’s Metabolism

Journal Articles

Skeletal Muscle TRIB3 Mediates Glucose Toxicity in Diabetes and High- Fat Diet–Induced Insulin Resistance

Wei Zhang, Mengrui Wu, Teayoun Kim, Ravi H. Jariwala, W. John Garvey, Nanlan Luo, Minsung Kang, Elizabeth Ma, Ling Tian, Dennis Steverson, Qinglin Yang, Yuchang Fu, W. Timothy Garvey

Diabetes 2016;65(8):2380–2391

https://doi.org/10.2337/db16-0154

Published: 10 May 2016

View articletitled, Skeletal Muscle TRIB3 Mediates Glucose Toxicity in Diabetes and High- Fat Diet–Induced Insulin Resistance

Includes: Supplementary data

Update search

NARROW

Format

Journal

Article Type

Topics

Issue Section

Date

Availability

231-OR: Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2

751-P: Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators—Exploratory Analysis of SURPASS 1–5 Trials

747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5

223-LB: Associations between Genetic Risk for Insulin Resistance and Measured Insulin Sensitivity Are Impacted by Race and BMI Status

71-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—SURMOUNT-1 Post Hoc Analysis by Prediabetes Status

70-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—Post Hoc Analysis of the SURMOUNT-1 Trial

51-LB: Race Specific Effects of a Carbohydrate-Restricted Diet on Acute and Maximal C Peptide Response to Glucose in Adults with Type 2 Diabetes

1118-P: Prediction of Clamp-Derived Insulin Sensitivity in African Americans from Clinical Risk Factors

2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity

1413-P: Semaglutide 2.4 mg Improved Glucose Metabolism and Reverted Prediabetes to Normoglycemia in Adults with Overweight/Obesity vs. Liraglutide 3.0 mg (STEP 8)

1210-P: Associations between HbA1c, Area Level Social Vulnerability, and Poor COVID-Outcomes

80-OR: Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis

83-OR: Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)

Tribbles Homolog 3 Mediates the Development and Progression of Diabetic Retinopathy

Serum Apolipoprotein C-III and Cardiovascular Events in Type 1 Diabetes

Cardiometabolic Disease Risk Assessment Predicts Incident Diabetes in a Large and Diverse Population

Uric Acid and Cardiovascular Disease in Type 1 Diabetes

The Induction of TRIB3 Causing Glucose Toxicity in Muscle Requires the O-GlcNAcylation of SP1

Maternal Dietary Manipulation Programs Offspring’s Metabolism

Skeletal Muscle TRIB3 Mediates Glucose Toxicity in Diabetes and High- Fat Diet–Induced Insulin Resistance

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Update search

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only